OncoCyte (OCX) News Today → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free OCX Stock Alerts $2.48 +0.04 (+1.64%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineOncoCyte (NASDAQ:OCX) Given New $4.25 Price Target at Needham & Company LLCamericanbankingnews.com - April 25 at 5:26 AMStrong Future Outlook for OncoCyte: Buy Rating and Increased Price Target Amid Positive Partnerships and Financial Efficiencymarkets.businessinsider.com - April 24 at 6:06 PMOncoCyte (NASDAQ:OCX) Earns Sell Rating from Analysts at StockNews.comamericanbankingnews.com - April 24 at 2:22 AMBuffett Grabs More of This Stock, Plus Other Notable Insider Buyingmsn.com - April 22 at 12:51 AMStephens Reiterates "Equal Weight" Rating for OncoCyte (NASDAQ:OCX)americanbankingnews.com - April 19 at 5:50 AMOncoCyte (NASDAQ:OCX) Now Covered by StockNews.comamericanbankingnews.com - April 18 at 2:30 AMOncoCyte Co. (NASDAQ:OCX) CEO Buys $10,000.50 in Stockinsidertrades.com - April 16 at 4:46 AMOncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcriptseekingalpha.com - April 13 at 10:47 PMQ4 2023 OncoCyte Corp Earnings Callfinance.yahoo.com - April 13 at 1:38 AMOCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023investorplace.com - April 12 at 12:00 PMTop 3 Health Care Stocks That May Collapse In Q2msn.com - April 12 at 10:36 AMOncoCyte Corporation: Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assayfinanznachrichten.de - April 12 at 10:10 AMS&P Futures Tick Lower as Investors Digest Big Bank Earningsmsn.com - April 12 at 10:10 AMS&P Futures Tick Lower as Investors Cautiously Await U.S. Big Bank Earningsmsn.com - April 12 at 7:32 AMOncocyte announces $15.8 mln private placement of securitiesmsn.com - April 12 at 7:32 AMOncocyte Reports Full Year 2023 Financial Resultsglobenewswire.com - April 12 at 6:00 AMOncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rulesglobenewswire.com - April 11 at 9:46 PMOncocyte and Bio-Rad Partner on Global Launch of Transplant Assayglobenewswire.com - April 11 at 5:30 PMHere's what Wall Street expects from Oncocyte's earningsmarkets.businessinsider.com - April 11 at 12:51 PMOncocyte to Announce Fourth Quarter and Full Year 2024 Financial Resultsglobenewswire.com - April 9 at 4:05 PMNeuroBo stock jumps 14% on weight-loss drug updatemsn.com - February 29 at 10:17 AMOncoCyte Stock (NASDAQ:OCX), Short Interest Reportbenzinga.com - February 24 at 8:37 PMOncocyte to Present at the Sequire Investor Summit in Puerto Ricofinance.yahoo.com - January 16 at 8:34 AMBTIG Reaffirms Their Hold Rating on OncoCyte (OCX)markets.businessinsider.com - January 7 at 10:19 PMOncoCyte Stock (NASDAQ:OCX) Dividends: History, Yield and Datesbenzinga.com - December 11 at 10:20 AMmarketbeat.com - December 8 at 3:29 PMOncocyte Begins FDA Submissions Process for VitaGraft Transplant Assaysfinance.yahoo.com - December 6 at 10:22 AMOncoCyte Corp OCXmorningstar.com - November 18 at 1:33 PMOncoCyte Corporation (NASDAQ:OCX) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 10 at 2:53 PMOncoCyte Corp (OCX) Reports Q3 2023 Financial Results with Key Product Launches on the Horizonfinance.yahoo.com - November 9 at 8:35 AMOncocyte Reports Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 9 at 8:07 AMOncocyte to Announce Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 3 at 9:33 AMOncocyte Corporation: Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlierfinanznachrichten.de - September 18 at 8:31 AMOncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlierfinance.yahoo.com - September 18 at 8:31 AMOncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - September 6 at 8:29 AMOncocyte Corporation: Oncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coveragefinanznachrichten.de - August 28 at 9:50 AMOncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coveragefinance.yahoo.com - August 28 at 9:29 AMBenchmark Maintains Oncocyte (OCX) Speculative Buy Recommendationnasdaq.com - August 24 at 11:51 PMPiper Sandler Maintains Oncocyte (OCX) Neutral Recommendationmsn.com - August 15 at 3:15 PMNeedham Maintains Oncocyte (OCX) Buy Recommendationmsn.com - August 11 at 1:19 AMOncocyte Corporation: Oncocyte Reports Second Quarter 2023 Financial Resultsfinanznachrichten.de - August 10 at 8:14 AMOncocyte Reports Second Quarter 2023 Financial Resultsfinance.yahoo.com - August 10 at 8:14 AMOncocyte Regains Compliance With Nasdaq Listing Requirementsfinance.yahoo.com - August 9 at 9:35 AMOncocyte Corporation: Oncocyte Regains Compliance With Nasdaq Listing Requirementsfinanznachrichten.de - August 9 at 8:28 AMOncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conferencefinance.yahoo.com - August 8 at 8:59 AMOncocyte To Announce Second Quarter 2023 Financial Resultsfinance.yahoo.com - August 3 at 8:05 AMOncocyte (OCX) Price Target Increased by 1900.00% to 7.14msn.com - August 2 at 10:18 AMVitaGraft Kidney Expands Utility in Recurrent Primary Disease Patientsfinance.yahoo.com - July 25 at 10:33 AMOncocyte Corporation: Oncocyte Announces 1-For-20 Reverse Stock Splitfinanznachrichten.de - July 25 at 6:48 AMOncocyte Announces 1-For-20 Reverse Stock Splitfinance.yahoo.com - July 24 at 3:34 PM Get OncoCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Email Address Protect Yourself While There’s Still Time … (Ad)The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom. 4 simple steps to protect your privacy and money before it’s too late. OCX Media Mentions By Week OCX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCX News Sentiment▼0.200.32▲Average Medical News Sentiment OCX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCX Articles This Week▼61▲OCX Articles Average Week Get OncoCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Cardio Diagnostics News DURECT News Trinity Biotech News Biomerica News Achilles Therapeutics News MyMD Pharmaceuticals News ImmuCell News Aspira Women's Health News ARCA biopharma News VolitionRx News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCX) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.